Ofir Wolach

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6540580/publications.pdf

Version: 2024-02-01

86	1,813	430442	288905
papers	citations	18 h-index	40 g-index

87	87	87	3091
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	5.8	299
2	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discovery, 2016, 6, 368-381.	7.7	215
3	Late-Onset Neutropenia After Rituximab Treatment. Medicine (United States), 2010, 89, 308-318.	0.4	137
4	How I treat mixed-phenotype acute leukemia. Blood, 2015, 125, 2477-2485.	0.6	126
5	Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatricâ€inspired regimens: Systematic review and metaâ€analysis. American Journal of Hematology, 2012, 87, 472-478.	2.0	118
6	Lymphoma and Leukemia Cells Possess Fractal Dimensions That Correlate with Their Biological Features. Acta Haematologica, 2008, 119, 142-150.	0.7	104
7	Neutropenia after rituximab treatment. Current Opinion in Hematology, 2012, 19, 32-38.	1.2	58
8	Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agentsâ€”a multicenter historical prospective study. Annals of Hematology, 2019, 98, 1927-1932.	0.8	56
9	Leucocyte adhesion deficiencyâ€”A multicentre national experience. European Journal of Clinical Investigation, 2019, 49, e13047.	1.7	54
10	Autoimmunity and Inflammation in Myelodysplastic Syndromes. Acta Haematologica, 2016, 136, 108-117.	0.7	45
11	Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Current Opinion in Hematology, 2017, 24, 139-145.	1.2	44
12	Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker. British Journal of Cancer, 2017, 117, 353-357.	2.9	38
13	Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia and Lymphoma, 2020, 61, 2221-2225.	0.6	30
14	Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias. European Journal of Haematology, 2018, 101, 297-304.	1.1	27
15	Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative diseaseâ€”a single center case series. Bone Marrow Transplantation, 2021, 56, 1031-1037.	1.3	25
16	Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric Bâ€cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. Pediatric Blood and Cancer, 2019, 66, e27898.	0.8	22
17	Variable Clinical expressivity of STAT3 Mutation in Hyperimmunoglobulin E Syndrome: Genetic and Clinical Studies of Six Patients. Journal of Clinical Immunology, 2014, 34, 163-170.	2.0	21
18	Blinatumomab for the Treatment of Philadelphia Chromosomeâ€“Negative, Precursor B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 4262-4269.	3.2	20

#	Article	IF	Citations
19	Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. American Journal of Hematology, 2021, 96, 790-795.	2.0	20
20	Optimal therapeutic strategies for mixed phenotype acute leukemia. Current Opinion in Hematology, 2020, 27, 95-102.	1.2	19
21	Safety and efficacy of blinatumomab: a real world data. Annals of Hematology, 2020, 99, 835-838.	0.8	19
22	Current challenges and opportunities in treating adult patients with Philadelphiaâ€negative acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 705-723.	1.2	18
23	Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hematoâ€oncological patients: Randomized controlled trial. American Journal of Hematology, 2014, 89, 243-248.	2.0	16
24	Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clinical Microbiology and Infection, 2018, 24, 749-754.	2.8	15
25	Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies â€“ a retrospective study. Leukemia and Lymphoma, 2019, 60, 2787-2792.	0.6	15
26	Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. Clinical Microbiology and Infection, 2022, 28, 303.e1-303.e4.	2.8	15
27	Allogeneic transplantation is not superior to chemotherapy in most patients over 40Âyears of age with Philadelphiaâ€negative acute lymphoblastic leukemia in first remission. American Journal of Hematology, 2016, 91, 793-799.	2.0	14
28	Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. Acta OncolÃ³gica, 2021, 60, 1335-1341.	0.8	14
29	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Annals of Hematology, 2022, 101, 379-387.	0.8	14
30	Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. Annals of Hematology, 2022, 101, 1719-1726.	0.8	14
31	Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remissionâ€"a multi-center historical control study. Annals of Hematology, 2019, 98, 2711-2717.	0.8	13
32	High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. Hematological Oncology, 2016, 34, 28-35.	0.8	12
33	A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DARTÂ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 2662-2662.	0.6	11
34	Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors. Cancers, 2022, 14, 119.	1.7	10
35	Late onset neutropenia after rituximab and obinutuzumab treatment â€“ characteristics of a class-effect toxicity. Leukemia and Lymphoma, 2021, 62, 2921-2927.	0.6	9
36	Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study. Hematological Oncology, 2015, 33, 42-47.	0.8	8

#	Article	IF	Citations
37	Casting a NET on cancer: the multiple roles for neutrophil extracellular traps in cancer. Current Opinion in Hematology, 2022, 29, 53-62.	1.2	8
38	Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood Advances, 2022, 6, 2835-2846.	2.5	8
39	Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e343-e348.	0.2	7
40	Autologous hematopoietic cell transplantation for AML in first remission â€“ An abandoned practice or promising approach?. Seminars in Hematology, 2019, 56, 139-146.	1.8	6
41	Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the Cracks. Acta Haematologica, 2014, 132, 279-291.	0.7	5
42	Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. Blood Advances, 2020, 4, 3822-3828.	2.5	5
43	Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. Leukemia and Lymphoma, 2021, 62, 2747-2754.	0.6	5
44	Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative. Blood, 2021, 138, 2328-2328.	0.6	5
45	Ethnic groups and high sensitivity C-reactive protein in Israel. Biomarkers, 2008, 13, 296-306.	0.9	4
46	Acute Promyelocytic Leukemia with a Smoldering Course Associated with Therapy-Related Myelodysplastic Syndrome. Acta Haematologica, 2011, 126, 152-156.	0.7	4
47	Increased Activity of Cell Membrane-Associated Prothrombinase, Fibrinogen-Like Protein 2, in Peripheral Blood Mononuclear Cells of B-Cell Lymphoma Patients. PLoS ONE, 2014, 9, e109648.	1.1	4
48	Analysis of Chronic Granulomatous Disease in the Kavkazi Population in Israel Reveals Phenotypic Heterogeneity in Patients with the Same NCF1 mutation (c.579G>A). Journal of Clinical Immunology, 2018, 38, 193-203.	2.0	4
49	Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication. Acta Haematologica, 2020, 143, 65-68.	0.7	4
50	Diarrheal Morbidity During Hematopoietic Cell Transplantation: The Diagnostic Yield of Stool Cultures. Infectious Diseases and Therapy, 2021, 10, 1023-1032.	1.8	4
51	Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol. Annals of Hematology, 2022, 101, 581-593.	0.8	4
52	Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?. Current Opinion in Hematology, 2015, 22, 123-131.	1.2	3
53	Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. British Journal of Clinical Pharmacology, 2015, 79, 685-691.	1.1	3
54	Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3â€ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission. European Journal of Haematology, 2021, 106, 64-71.	1.1	3

#	Article	IF	Citations
55	Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. Hemato, 2021, 2, 305-328.	0.2	3
56	Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management. Scientific Reports, 2021, 11, 11940.	1.6	3
57	First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study. Blood, 2020, 136, 27-28.	0.6	3
58	Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. Leukemia Research, 2022, 113, 106773.	0.4	3
59	The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1977-1979.	0.6	2
60	Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment. Leukemia and Lymphoma, 2020, 61, 2708-2713.	0.6	2
61	Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients â€“ a multicenter retrospective observational study. Leukemia and Lymphoma, 2021, 62, 1-7.	0.6	2
62	Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. Blood, 2020, 136, 26-28.	0.6	2
63	Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation. Blood, 2015, 126, LBA-4-LBA-4.	0.6	2
64	Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative. Blood, 2021, 138, 1271-1271.	0.6	2
65	Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. Annals of Hematology, 2020, 99, 2939-2945.	0.8	1
66	Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.. Journal of Clinical Oncology, 2021, 39, 7007-7007.	0.8	1
67	Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 5899-5899.	0.6	1
68	Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation. Blood, 2016, 128, 633-633.	0.6	1
69	Adolescents and Young Adults with Acute Lymphoblastic Leukemia Have Better Outcomes When Treated with Pediatric-Inspired Regimens - Systematic Review and Meta-Analysis of Comparative Trials. Blood, 2011, 118, 2591-2591.	0.6	1
70	Autoimmune and Inflammatory Manifestations Associated with Acute Myeloid Leukemia with Trisomy 8 â€“ Case Series and Review of the Literature.. European Journal of Haematology, 2021, , .	1.1	1
71	Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation. Blood, 2021, 138, 4876-4876.	0.6	1
72	Leukemic Phase of Histiocytic Sarcoma of the Digestive System: A Rare Manifestation of a Rare Disease. Acta Haematologica, 2021, 144, 229-235.	0.7	0

#	Article	IF	Citations
73	From the Editorâ€™s Desk: Publishing in Times of a Pandemic. Acta Haematologica, 2021, 144, 473-475.	0.7	0
74	Limited PET-CT May Be Adequate for Interim and End of Therapy Response Assessment in Patients with Early Stage Hodgkin and Aggressive Non-Hodgkin Lymphoma - A Retrospective Single Center Study. Blood, 2011, 118, 1562-1562.	0.6	0
75	Increased Activity of Prothrombinase Fgl-2 in Peripheral Blood Mononuclear Cells of Patients with B-Cell Lymphoma.. Blood, 2012, 120, 2665-2665.	0.6	0
76	Continuous Platelet Transfusion Increases Platelet Increment in Refractory Hemato-Oncological Patients â€“ a Single Center Experience. Blood, 2014, 124, 2888-2888.	0.6	0
77	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. Blood, 2015, 126, 1304-1304.	0.6	0
78	Risk Factors for Early Mortality in Hemato-Oncological Patients with Carbapenem Resistant Acinetobacter Baumannii (CRAB) Bacteremia. Blood, 2018, 132, 4953-4953.	0.6	0
79	Sequential Treatment with FLAG-IDA Salvage Chemotherapy Followed By Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia. Blood, 2018, 132, 5788-5788.	0.6	0
80	The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment. Blood, 2019, 134, 5110-5110.	0.6	0
81	Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b. Blood, 2019, 134, 179-179.	0.6	0
82	Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study. Blood, 2021, 138, 1273-1273.	0.6	0
83	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study. Blood, 2021, 138, 3962-3962.	0.6	0
84	Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy. Blood, 2020, 136, 12-13.	0.6	0
85	Diarrheal Morbidity in Patients Undergoing Hematopoietic Cell Transplantation - the Diagnostic Yield of Stool Cultures. Blood, 2020, 136, 26-27.	0.6	0
86	Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. Blood, 2020, 136, 9-10.	0.6	0